BRPI0511153A - método para tratamento do crescimento celular anormal - Google Patents

método para tratamento do crescimento celular anormal

Info

Publication number
BRPI0511153A
BRPI0511153A BRPI0511153-6A BRPI0511153A BRPI0511153A BR PI0511153 A BRPI0511153 A BR PI0511153A BR PI0511153 A BRPI0511153 A BR PI0511153A BR PI0511153 A BRPI0511153 A BR PI0511153A
Authority
BR
Brazil
Prior art keywords
derivative
cell growth
abnormal cell
treating abnormal
canptothecin
Prior art date
Application number
BRPI0511153-6A
Other languages
English (en)
Inventor
Langdon Leforrest Miller
Louis Jean Denis
Linda Darlene Compton
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0511153A publication Critical patent/BRPI0511153A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODO PARA TRATAMENTO DO CRESCIMENTO CELULAR ANORMAL Descrevem-se composições farmacêuticas terapêuticas e métodos de tratamento do crescimento celular anormal compreendendo um derivado de pirimidina ou um sal, solvato ou prodroga farmaceuticamente aceitável deste em combinação com uma canptotecina oral ou derivado de canptotecina oral, um derivado de indolpirrocarbazol ou um sal, solvato ou prodroga farmaceuticamente aceitável deste para tratamento do câncer. Em uma modalidade da presente invenção o derivado de canptotecina oral é selecionado do grupo consistindo de 10-hidroxicanptotecina, 9-aminocanptotecina, 9-nitrocanptotecina, irinotecan, sal de irinotecan, SN-38, CPT-11 e topotecan e o derivado de indolpirrocarbazol é edotecarina. Numa modalidade o derivado de pirimidina é selecionado do grupo consistindo de gencitabina, MTA e capecitabina. Numa modalidade preferida, o derivado de pirimidina é capecitabina e o derivado de canptotecina é CPT-11.
BRPI0511153-6A 2004-05-28 2005-05-17 método para tratamento do crescimento celular anormal BRPI0511153A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57514504P 2004-05-28 2004-05-28
PCT/IB2005/001467 WO2005115391A1 (en) 2004-05-28 2005-05-17 Method for treating abnormal cell growth

Publications (1)

Publication Number Publication Date
BRPI0511153A true BRPI0511153A (pt) 2007-12-04

Family

ID=34968482

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511153-6A BRPI0511153A (pt) 2004-05-28 2005-05-17 método para tratamento do crescimento celular anormal

Country Status (7)

Country Link
US (1) US20050267140A1 (pt)
EP (1) EP1771174A1 (pt)
JP (1) JP2008501007A (pt)
BR (1) BRPI0511153A (pt)
CA (1) CA2566156A1 (pt)
MX (1) MXPA06013902A (pt)
WO (1) WO2005115391A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP5190958B2 (ja) 2005-07-14 2013-04-24 ウェルスタット バイオロジクス コーポレイション ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置
US20100144678A1 (en) * 2007-04-09 2010-06-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating bone cancer
TR201904459T4 (tr) * 2010-11-12 2019-05-21 Pharma Mar Sa Bir mitotik inhibitör ile kombinasyon terapisi.
RU2477641C1 (ru) * 2011-09-30 2013-03-20 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН Способ лечения рака прямой кишки
ES2680444T3 (es) 2014-01-17 2018-09-07 Oncoral Pharma Aps Forma de dosificación oral sólida de irinotecán para el tratamiento del cáncer
CN106714807A (zh) * 2014-01-28 2017-05-24 周文强 喜树碱衍生物在制备用于治疗多发性骨髓瘤的药物中的用途
CN117881398A (zh) * 2021-09-05 2024-04-12 台睿生物科技股份有限公司 具有增强的sn-38溶解度及口服吸收的配方

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60124387T2 (de) * 2000-02-28 2007-10-11 Pfizer Enterprises Sarl. Synergistische pharmazeutische Zusammensetzungen zur Behandlung von kolorektalem Krebs
JP2005008534A (ja) * 2003-06-17 2005-01-13 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) 抗癌剤及び癌の治療方法

Also Published As

Publication number Publication date
WO2005115391A1 (en) 2005-12-08
JP2008501007A (ja) 2008-01-17
EP1771174A1 (en) 2007-04-11
MXPA06013902A (es) 2007-01-26
US20050267140A1 (en) 2005-12-01
CA2566156A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
BRPI0511153A (pt) método para tratamento do crescimento celular anormal
Tentori et al. Inhibition of poly (ADP‐ribose) polymerase prevents irinotecan‐induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma
CA3155857A1 (en) PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
IL251185A0 (en) mek inhibitors and methods of using them
DE60328486D1 (de) Zusammensetzungen und verfahren zur beschichtung medizinischer implantate
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
PT1307197E (pt) Composicoes para o tratamento do cancro compreendendo um inibidor de topoisomerase e talidomida
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
Oza et al. Homologous recombination repair deficiency as a therapeutic target in sarcoma
EA201170090A1 (ru) Пиразолохиназолины
RU2017119066A (ru) Композии апилимода и способы их применения в лечении колоректального рака
DE602007006663D1 (de) Verfahren zur behandlung von krebs
DK1278518T3 (da) Synergistisk kombination til behandling af colorektal cancer
Kasper et al. Novel treatment strategies for soft tissue sarcoma
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
Baka et al. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer
WO2007110705A3 (en) Macrolide as inhibitors of mhc class ii
BRPI0606365A2 (pt) composto ou um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo e estereoisômeros e tautômeros do mesmo, composição farmacêutica, métodos para prevenir, tratar, melhorar ou controlar uma doença ou condição e para preparar um composto, uso de um composto ou um sal, solvato ou composição farmaceuticamente aceitável do mesmo, método de tratamento de um mamífero, e, combinação
WO2007110704A3 (en) Macrolide compositions as therapeutic agent
Maroun et al. A National Cancer Institute of Canada Clinical Trials Group Study–IND. 135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex)(COT) in patients with advanced colorectal cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.